China Reassures Public On Usage Of Topical Ibuprofen
This article was originally published in PharmAsia News
Executive SummaryFollowing U.S. FDA's recent warning to eight U.S. manufacturers of topical ibuprofen, China's State FDA has given its assurance that according to China's safety data, the drug does not show serious adverse reactions other than itching, flush and rash
You may also be interested in...
With a global supply chain and commercial platform, the Viatris entity to be formed by the merger of Mylan and Pfizer’s Upjohn unit wants to be the partner of choice for mid-sized products overlooked by companies focused on blockbusters.
Ongoing launches, relatively stable market conditions and cost-cutting initiatives are producing record profits from Teva’s European operations, president and CEO Kåre Schultz told delegates to a J.P. Morgan Healthcare Conference.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.